Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by davewhoon Feb 20, 2021 1:21pm
165 Views
Post# 32619042

RE:RE:RE:RE:SZLS and CBDT labs

RE:RE:RE:RE:SZLS and CBDT labsmarket cap for CBDT is now almost $500m since that move up yesterday. There is a reason James isn't saying anything we just don't know what it is. Is he even calling the shots now or are the 3 institutions calling the shots? Someone wise once told me that if you ask a question and get no answer then strangely the silence is an answer.
they don't know the answer
they don't want you to know the answer
they don't want the competition to know the answer
and others
we will find out soon enough though. Yes we have all waited many years but what is another 6 weeks?
In my reading about LDT's labs have the option of filing a 510K which basically alerts the FDA to your new test and they then have to look at it. The pro active approach to launch. The worst thing would be for Aristotle to launch and spend M's$ in marketing only to have the FDA pull the plug and say we need 90 days to look at the validation data. Grail and Exas won't be happy to hear of Aristotle launch and will likely be on the phone to the FDA. Not saying SZLS will take that route but it is an option for them. The projected market for tests like Aristotle is huge but it would be nice to be the first and established before the competition is launched.
Launch then market Aristotle is probably the best way to go in my mind. Could they provide a rev update or covid test number update? Sure. But they obviously don't want to. Yet.
<< Previous
Bullboard Posts
Next >>